Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Dikiltas, M."'
Autor:
Kos Ft, Abdurrahman Isikdogan, Ilkay Tugba Unek, Suleyman Buyukberber, Mahmut Gumus, Dikiltas M, Efnan Algin, Mustafa Benekli, Muhammet Ali Kaplan, Faysal Dane, Gamze Goksel, Metin Ozkan, Emin Tamer Elkiran, Ozan Balakan, H Harputoglu, Mehmet Kucukoner, Kaan Helvaci, Ayse Durnali, Nalan Özdemir, Rıfat Yıldız, Dilsen Colak, Dogan Uncu, C. Geredeli, Ali Inal
Publikováno v:
Neoplasma. 59:297-301
The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::091687165338dcbb7ff14cd9d3b322b8
https://doi.org/10.4149/neo_2012_038
https://doi.org/10.4149/neo_2012_038
Autor:
Dikiltas, M., Helvaci, K., Geredeli, C., Gumus, M., Kucukoner, M., Inal, A., Kos, F. T., Ozkan, M., Uncu, D., Buyukberber, S., Ozdemir, N., Goksel, G., Harputoglu, H., Durnali, A. G., Kaplan, M. A., Balakan, O., Dane, F., Benekli, M., Isikdogan, A., ÜNEK, İLKAY TUĞBA, Algin, E., Yildiz, R., Colak, D., ELKIRAN, EMİN TAMER
Publikováno v:
Neoplasma. 59(3)
The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6e9dd7202562454f935b89e06b3a70f0
https://pubmed.ncbi.nlm.nih.gov/22329849
https://pubmed.ncbi.nlm.nih.gov/22329849
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
DANE, FAYSAL
The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3098::7f9a3eaa2974751f1d3d45c928b00d7b
https://hdl.handle.net/11424/245443
https://hdl.handle.net/11424/245443
